World Cancer Day: Insuring Against Cancer January 31, 2022

World Cancer Day: Insuring Against Cancer

For the past two years, COVID-19 has hogged the headlines. But when it comes to health issues, there are other killers out there.

And to remind us of the danger, World Cancer Day is being marked on February 4.

Cancer was a leading cause of death worldwide in 2020, and accounted for nearly 10 million deaths that year, according to the World Health Organisation1.

The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).

The most common causes of cancer death in 2020 were: lung (1.80 million deaths); colon and rectum (935 000 deaths); liver (830 000 deaths); stomach (769 000 deaths); and breast (685 000 deaths).

The economic impact of cancer is also significant and increasing. And the total annual economic cost of cancer in 2010 was estimated at US$ 1.16 trillion.
Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumours and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs.

The latter process is referred to as metastasis, and metastases are the primary cause of death from cancer.

Reducing the burden

Between 30 and 50% of cancers can currently be prevented by avoiding risk factors and implementing existing evidence-based prevention strategies.

The cancer burden can also be reduced through early detection of cancer and appropriate treatment and care of patients who develop cancer. Many cancers have a high chance of cure if diagnosed early and treated appropriately.

Preventing the disease

Cancer risk can be reduced by not using tobacco; maintaining a healthy body weight; eating a healthy diet and including fruit and vegetables.

You can also reduce your cancer risk by doing physical activity on a regular basis; avoiding harmful use of alcohol; getting vaccinated against HPV and hepatitis B if you belong to a group for which vaccination is recommended.

Top killer in Singapore

In Singapore today, cancer is regarded as Singapore’s top killer, and it is responsible for 28.4% of all deaths in the country.2

In 2020 the total number of new cancer cases in Singapore was reported to be 23,632. Of these cases, 12,196 were males and 11,436 were females.

In the same year, there were 12,130 deaths reported due to cancer. Taken as a percentage of the total number of prevalent cases in Singapore (69,267), this amounts to 17% of all current cases.

A large majority of deaths due to cancer in 2020 were caused by lung cancer, liver cancer, colon cancer, breast cancer, and pancreatic cancer.

According to the Singapore Cancer Registry, the majority of male cancer cases between 2014 and 2018 were seen in the 60 to 69-year-old age group. In contrast to this, the lowest number of cancer cases were seen in men below the age of 30. For women, the data is quite similar.

Depending on the type of cancer, a patient can end up paying from $100,000 to $200,000 for late-stage care. This high cost is a result of the expensive cancer drugs used in a majority of treatments.

In 2019, Singapore spent $375 million on cancer treatment drugs. This figure represents a 20% growth rate for national expenses on cancer drugs.

This is over three times higher than the 6% growth rate for national expenses for non-cancer drugs. Many experts believe that if this rate of growth continues, the country may end up spending upwards of $2 billion by 2030.

So, how does one cope financially if you are afflicted by cancer?

Health insurance is the best option. And thankfully there are many choices available today.

Who should consider medical insurance against cancer?

1 – Who should consider medical insurance against cancer?

If you look at the statistics, the answer seems obvious. Everyone should sign up when you are healthy. So find the insurer that suits your needs and affordability through PhillipCapital’s experienced financial advisers who represents different firms.

Related video: The role of insurance in your journey

What are some of the types of protection plans available against the disease?

There are various types of protection plans available to protect you.

Some of them are:

  • Critical Illness standalone term plans (cheaper premium) without cash value.
  • Whole life policies with critical Illness coverage and bonus from the insurer (higher premium).
  • Critical illness plans which covers heart attacks, cancer, stroke etc (Under standard life insurance guide).
  • • You can also get gender-specific coverage for men and women (prostate cancer for men and breast cancer for women).

• World Cancer Day 2022 falls on February 4, World Cancer Day is a global initiative led by the Union for International Cancer Control to face one of our greatest challenges. The 2022 Campaign Theme is “Close the Care Gap / Realising the problem”3.



These commentaries are intended for general circulation. It does not have regard to the specific investment objectives, financial situation and particular needs of any person who may receive this document. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. Investors may wish to seek advice from a financial adviser before investing. In the event that investors choose not to seek advice from a financial adviser, they should consider whether the investment is suitable for them.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066